Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1221781 | 0.89 | KCNH2 (0.48) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL20209685 | 0.88 | KCNH2 (0.52) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL28018296 | 0.88 | KCNH2 (0.52) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL21186452 | 0.88 | KCNH2 (0.52) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL21645767 | 0.88 | KCNH2 (0.52) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| Alcohol SCHEMBL22495162 | 0.84 | KCNH2 (0.44) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL6049592 | 0.84 | — | — | |
| Ammonia Solution, Strong SCHEMBL6014423 | 0.82 | CYP1A2 (0.42) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL29244185 | 0.77 | MIF (0.36) | KCNH2CYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL22266323 | 0.76 | SIGMAR1 (0.46) | KCNH2CYP1A2CYP2D6L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629149-B2 | Oxopiperazine derivatives for the treatment of pain and epilepsy | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-14 | — | — | US | disclosed |
| CN-102656151-A | Substituted heterocyclic derivatives for the treatment of pain and epilepsy | ZALICUS PHARMACEUTICALS LTD | 2012-09-05 | — | — | CN | disclosed |
| US-20120220605-A1 | OXOPIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-08-30 | — | — | US | disclosed |
| EP-2473488-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026241-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220603-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | CACNA1B, SCN1A, CACNA1I | KCNH2 40/4885CYP1A2 286/4885CYP2D6 688/4885 |
| US-20120220605-A1 | OXOPIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN AND EPILEPSY | CACNA1H, CACNG7, CACNA1I | KCNH2 17/4885CYP1A2 1641/4885CYP2D6 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.